title: Treatment of Locally Advanced Non-Small Cell Lung Cancer.
abstract: Locally advanced non-small cell lung cancer is a heterogeneous disease with typically poor outcomes. Select patients may benefit from the integration of surgery, whereas patients with bulky, multistation, or contralateral (N3) mediastinal involvement are managed with definitive chemoradiation. Attempts to improve outcomes through induction, consolidation, or maintenance chemotherapy or radiation dose escalation have not demonstrated a survival benefit. Current research efforts focus on the integration of novel systemic agents that exploit tumor-specific driver mutations, augment antitumor immune response, or enhance radiation sensitivity.
authors.affiliation: University of California Davis Medical Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA.
authors.forename: Kit
authors.initials: K
authors.lastname: Tam
authors.affiliation: University of California Davis Medical Center, 4501 X Street, Suite G-140, Sacramento, CA 95817, USA.
authors.forename: Megan
authors.initials: M
authors.lastname: Daly
authors.affiliation: University of California Davis Medical Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA. Electronic address: karkelly@ucdavis.edu.
authors.forename: Karen
authors.initials: K
authors.lastname: Kelly
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D017239:Paclitaxel / Q000627:therapeutic use; D011879:Radiotherapy Dosage
chemical_list: D005047:Etoposide; D016190:Carboplatin; D017239:Paclitaxel
keywords: Chemoradiation; Locally advanced disease; Non–small cell lung cancer